Pembrolizumab,Vibostolimab,Favezelimab
merck
['mibc', 'pembro', 'key,note,45', 'key,note,57', 'nmibc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'kn57', 'bladder']
a takeover of for onclive pembro in bcg refractory nmibc papillary g3 ta/t1 cohort kn57. &gt;100 patients. 12 month dfs of 43% . however there is so little data in this area it s very difficult to quantify. randomised trials are tricky but needed. #gu23 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.